Espicom's generics company reports will help you to understand the dynamic and complex issues affecting the business of leading generic industry players. These informative reports provide an insight into the company, covering the structure of the business, the most recent quarterly and annual financial results, information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances, and litigation. Cadila was founded in 1952, and was restructured in 1992 to become the Zydus Cadila Group. Cadila Healthcare, the Group's flagship company, was launched as an IPO in February 2000. The Zydus Group is aiming to become one of the top three healthcare companies in India and a global player. It has made forays into the US and EU markets, and other markets, such as Brazil, South Africa and Algeria. It plans to start selling in Japan in 2007.

In July 2003, Zydus signed an agreement to acquire Alpharma SAS France, which it has renamed Zydus France. The acquisition gave the company an established distribution network and a pipeline of 109 generic registrations.

In May 2005, Cadila Healthcare and Australia's Mayne Pharma announced they had signed a 50:50 joint venture, based in Gujarat. The company will manufacture generic injectable cytotoxic medicines and active pharmaceutical ingredients for the global markets.

In December 2005, Zydus announced it had entered into a joint venture agreement with the Indian biotech firm, Bharat Serums and Vaccines to create a company that will develop, manufacture and market a non-infringing and proprietary novel drug delivery system of an approved anti-cancer drug.

In April 2006, Zydus announced that its French subsidiary was strengthening its presence in France through an agreement with Evolupharn, the second largest ‘groupment' in France. The agreement will provide access to 2,250 more pharmacists.

In April 2006, Zydus also announced that it had accepted an offer of 7 million euros from Aerocid for 29 products in Zydus France's branded business. The products had originally been acquired from Alpharma in France in 2003 for 3.7 million euros, and are a mixture of mature prescription and OTC products. Zydus sold the products as part of an effort to concentrate on its core generics business.